ArticleChina CDC weekly2023
The Associated Factors of SARS-CoV-2 Reinfection by Omicron Variant - Guangdong Province, China, December 2022 to January 2023.
Article in China CDC weekly, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Therapeutic potential of mesenchymal stromal cells in COVID-19: a meta-analysis of clinical trials conducted since the pandemic onset.Stem cell research & therapy · 2026Pooled it
- Incidence, severity, risk factors and outcomes of SARS-CoV-2 reinfections during the Omicron period: a systematic review and meta-analysis.Journal of global health · 2025Pooled it
- Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial.Stem cell research & therapy · 2025Trial
- Article
- Susceptibility of human neural stem cells to SARS-CoV-2: Entry mechanisms and glycocalyx influence.PloS one · 2026Article
- First insight into eosinophils as a biomarker for the early distinction of COVID-19 from influenza A in outpatients.Experimental and therapeutic medicine · 2025Article
- Characteristics and risk factors associated with COVID-19 reinfection in Hong Kong: a retrospective cohort study.Epidemiology and infection · 2025Article
- Pregnancy outcomes and early infancy physical growth of fetal situs inversus during the COVID-19 pandemic.Frontiers in medicine · 2025Article
- Analysis of COVID-19 reinfection and its influencing factors among primary healthcare workers in Jiangsu Province: a study based on the omicron variant epidemic.Frontiers in public health · 2025Article
- Predicting higher risk factors for COVID-19 short-term reinfection in patients with rheumatic diseases: a modeling study based on XGBoost algorithm.Journal of translational medicine · 2024Article
- Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study.Signal transduction and targeted therapy · 2024Article
- The symptoms and interval of Omicron SARS-CoV-2 reinfection among healthcare workers in a hospital of Southern China: a cross-sectional study.BMC infectious diseases · 2024Article
- SARS-CoV-2 reinfection with Omicron variant in Shaanxi Province, China: December 2022 to February 2023.BMC public health · 2024Article
- Mapping knowledge structure and emerging trends of extracorporeal membrane oxygenation for acute respiratory distress syndrome: a bibliometric and visualized study.Frontiers in medicine · 2024Article
- The serological IgG and neutralizing antibody of SARS-CoV-2 omicron variant reinfection in Jiangsu Province, China.Frontiers in public health · 2024Article
- The Efficacy and Safety of Shashen-Maidong Decoction Combined with Western Medicine in the Treatment of Omicron Infected Individuals Over 85 Years Old: A Retrospective Study.Infection and drug resistance · 2023Article
- Epidemiological and clinical characteristics of COVID-19 reinfection during the epidemic period in Yangzhou city, Jiangsu province.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection by variants is being reported commonly and has caused waves of epidemic in many countries. Because of dynamic zero policy, the SARS-CoV-2 reinfection was less reported in China. What is added by this report?: SARS-CoV-2 reinfections were observed in Guangdong Province between December 2022 and January 2023. This study estimated that the reinfection incidence was 50.0% for the original strain primary infections, 35.2% for the Alpha or Delta variants, and 18.4% for the Omicron variant; The reinfection incidence within 3-6 months after primary infection by Omicron variant was 4.0%. Besides, 96.2% reinfection cases were symptomatic while only 7.7% sought medical attention. What are the implications for public health practice?: These findings suggest a reduced likelihood of an Omicron-driven epidemic resurgence in the short term but emphasize the importance of maintaining vigilant surveillance of emerging SARS-CoV-2 variants and conducting population-based antibody level surveys to inform response preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.